Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evexomostat + eribulin
- Development stage
- Phase 2
- Lead developer
- SynDevRx
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Evexomostat + eribulin is a combination therapeutic regimen being developed by SynDevRx for the treatment of insulin-resistant, metastatic triple-negative breast cancer (mTNBC). Evexomostat (formerly SDX-7320) is a small molecule inhibitor of Methionine Aminopeptidase 2 (MetAP2). MetAP2 inhibition is intended to address the metabolic drivers of cancer, such as hyperinsulinemia and chronic inflammation, which are often associated with poor prognosis and resistance to chemotherapy. Eribulin (Halaven) is a non-taxane microtubule dynamics inhibitor that induces cell cycle arrest in the G2/M phase. The combination is currently being evaluated in the Phase 2 Aretha-1 study, targeting patients whose tumors may be driven by metabolic dysfunction.
- Other names
- SDX-7320 + eribulinEvexomostat + Eribulin (Halaven)Aretha-1 StudyAretha1 StudyAretha 1 Study
02
Targets
METAP2 (Methionine aminopeptidase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on evexomostat + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evexomostat + eribulin.